DOCSLIB.ORG

Structure–Based Identification of OATP1B1/3 Inhibitors Molecular Pharmacology Compound Name Percent of Control 1B3 Percent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Structure–Based Identification of OATP1B1/3 Inhibitors Molecular Pharmacology Compound Name Percent of Control 1B3 Percent Structure–based identification of OATP1B1/3 inhibitors Tom De Bruyn, Gerard J.P. Van Westen, Adriaan P. IJzerman, Bruno Stieger, Peter de Witte, Patrick F. Augustijns and Pieter P. Annaert Molecular Pharmacology Complete dataset on % inhibition of sodium fluorescein (10 µM) uptake in OATP1B1 and OATP1B3-transfected CHO cells by all compounds (10 µM) used for building the in silico model. For compounds tested at different concentrations, pIC50 values are also shown. Compound name percent_of_control_1B3 percent_of_control_1B1 Smiles InChI InChIKey pIC50_1B3 pIC50_1B1 CARMINIC ACID 121.8970734 21.61023724 c(c1O[H])(C2=O)c(c(c([O-])c1O[C@@]3([H])O[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]([H])(O[H])[C@@]3([H])O[H])O[H])O[H])C(c(c([H])c(O[H])c4C([O-])=O)c2c4C([H])([H])[H])=O InChI=1S/C22H20O14/c1-4-8-5(2-6(24)9(4)21(33)34)12(25)10-11(14(8)27)16(29)20(18(31)15(10)28)36-22-19(32)17(30)13(26)7(3-23)35-22/h2,7,13,17,19,22-24,26,28-32H,3H2,1H3,(H,33,34)/p-2/t7-,13-,17+,19-,22-/m1/s1 FTZKEIWUUDUSNG-UZYNOIPLSA-L 3,7-DIMETHOXYFLAVONE 144.5632333 59.2805931 C(OC([H])([H])[H])(C(=O)c(c([H])c([H])c(c1[H])OC([H])([H])[H])c1O2)=C2c3c([H])c([H])c([H])c([H])c3[H] InChI=1S/C17H14O4/c1-19-12-8-9-13-14(10-12)21-16(17(20-2)15(13)18)11-6-4-3-5-7-11/h3-10H,1-2H3 CNDZOPXQZSXGSK-UHFFFAOYSA-N CARNOSINE 98.8638076 26.43693974 n1c([H])n([H])c([H])c1C([H])([H])[C@]([H])(N([H])C(=O)C([H])([H])C([H])([H])[N+]([H])([H])[H])C([O-])=O InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)/t7-/m0/s1 CQOVPNPJLQNMDC-ZETCQYMHSA-N KARANJIN 124.739521 50.38982717 C1([O-])=C(c2c([H])c([H])c([H])c([H])c2[H])Oc(c3C1=O)c([H])c([H])c(oc4[H])c3c4[H] InChI=1S/C17H10O4/c18-15-14-11-8-9-20-12(11)6-7-13(14)21-17(16(15)19)10-4-2-1-3-5-10/h1-9,19H/p-1 RFTCASQIXQHXFX-UHFFFAOYSA-M 6,4'-DIMETHOXYFLAVONE 110.4433729 34.4446499 C(c1c([H])c([H])c(c([H])c1[H])OC([H])([H])[H])(Oc(c([H])c([H])c(c2[H])OC([H])([H])[H])c2C3=O)=C3[H] InChI=1S/C17H14O4/c1-19-12-5-3-11(4-6-12)17-10-15(18)14-9-13(20-2)7-8-16(14)21-17/h3-10H,1-2H3 ANVFDWBCVDQNEZ-UHFFFAOYSA-N BERGENIN 94.52147061 14.58593007 c12c(c([H])c(O[H])c(OC([H])([H])[H])c1O[H])C(=O)O[C@@]([H])([C@]([H])([C@]([H])(O[H])[C@@]([H])(C([H])([H])O[H])O3)O[H])[C@@]23[H] InChI=1S/C14H16O9/c1-21-11-5(16)2-4-7(9(11)18)12-13(23-14(4)20)10(19)8(17)6(3-15)22-12/h2,6,8,10,12-13,15-19H,3H2,1H3/t6-,8-,10+,12-,13+/m1/s1 YWJXCIXBAKGUKZ-BPTACTMOSA-N 7,2'-DIMETHOXYFLAVONE 110.459106 95.81702508 C1(c2c([H])c([H])c([H])c([H])c2OC([H])([H])[H])=C([H])C(c(c([H])c([H])c(OC([H])([H])[H])c3[H])c3O1)=O InChI=1S/C17H14O4/c1-19-11-7-8-12-14(18)10-17(21-16(12)9-11)13-5-3-4-6-15(13)20-2/h3-10H,1-2H3 WVWDHKIZBHIGJE-UHFFFAOYSA-N CARYLOPHYLLENE OXIDE 80.12043514 54.10267524 C1(C([H])([H])[H])(C([H])([H])C2([H])[H])C([H])(O1)C([H])([H])C([C@@]([H])(C([H])([H])C3(C([H])([H])[H])C([H])([H])[H])[C@@]23[H])=C([H])[H] InChI=1S/C14H22O/c1-9-7-12-14(4,15-12)6-5-11-10(9)8-13(11,2)3/h10-12H,1,5-8H2,2-4H3/t10-,11-,12?,14?/m1/s1 AMTSLHRSERHBCF-IBQNZTRDSA-N URSOCHOLANIC ACID 102.6659746 98.44612291 [C@@]1(C([H])([H])[H])(C([H])([H])C2([H])[H])C([H])(C([H])([H])C([H])([H])[C@]1([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([O-])=O)C([H])(C23[H])C([H])([H])C([H])([H])[C@]([H])(C([H])([H])C([H])([H])C([H])([H])C4([H])[H])[C@@]34C([H])([H])[H] InChI=1S/C24H40O2/c1-16(7-12-22(25)26)19-10-11-20-18-9-8-17-6-4-5-14-23(17,2)21(18)13-15-24(19,20)3/h16-21H,4-15H2,1-3H3,(H,25,26)/p-1/t16?,17-,18?,19+,20?,21?,23-,24+/m0/s1 RPKLZQLYODPWTM-UHJJYCRNSA-M CHOLEST-5-EN-3-ONE 103.4578743 119.6796 [C@@]1(C([H])([H])[H])(C([H])([H])C2([H])[H])C([H])(C([H])([H])C([H])([H])[C@]1([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])C([H])(C23[H])C([H])([H])C([H])=C(C([H])([H])C(=O)C([H])([H])C4([H])[H])[C@@]34C([H])([H])[H] InChI=1S/C27H44O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,22-25H,6-8,10-17H2,1-5H3/t19?,22?,23-,24?,25?,26+,27-/m1/s1 GGCLNOIGPMGLDB-IVFFKYSXSA-N [C@@]1([H])(O[C@]([H])([C@@]([H])(N([H])[H])C([H])([H])[C@]([H])([C@]2([H])O[C@@]3([H])O[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]([H])(N([H])[H])[C@@]3([H])O[H])O[H])N([H])[H])[C@]2([H])O[H])O[C@@]([H])([C@@]([H])(O[H])[C@]([H])(O[H])[C@@]1([H])[N+]([H])([H])[H])C([H])([H])N([H] BEKANAMYCIN SULFATE 118.1211282 101.9281723 )[H] InChI=1S/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2/p+1/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1 SKKLOUVUUNMCJE-FQSMHNGLSA-O CITRULLINE 119.6734612 135.0929369 C(N([H])[H])(N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([N+]([H])([H])[H])C([O-])=O)=O InChI=1S/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12) RHGKLRLOHDJJDR-UHFFFAOYSA-N GENKWANIN 107.0397778 116.7093215 c12c(c([H])c(OC([H])([H])[H])c([H])c1[O-])OC(=C([H])C2=O)c3c([H])c([H])c(c([H])c3[H])[O-] InChI=1S/C16H12O5/c1-20-11-6-12(18)16-13(19)8-14(21-15(16)7-11)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3/p-2 JPMYFOBNRRGFNO-UHFFFAOYSA-L S-ISOCORYDINE (+) 102.1415378 115.2241823 c(c(C([H])([H])C([H])([H])N1C([H])([H])[H])c([H])c(c2OC([H])([H])[H])OC([H])([H])[H])([C@]1([H])C([H])([H])c(c34)c([H])c([H])c(OC([H])([H])[H])c3O[H])c24 InChI=1S/C20H23NO4/c1-21-8-7-12-10-15(24-3)20(25-4)18-16(12)13(21)9-11-5-6-14(23-2)19(22)17(11)18/h5-6,10,13,22H,7-9H2,1-4H3/t13-/m0/s1 QELDJEKNFOQJOY-ZDUSSCGKSA-N 4-METHYLESCULETIN 110.1129777 121.7467532 c1(OC(=O)C([H])=C2C([H])([H])[H])c2c([H])c(O[H])c([O-])c1[H] InChI=1S/C10H8O4/c1-5-2-10(13)14-9-4-8(12)7(11)3-6(5)9/h2-4,11-12H,1H3/p-1 KVOJTUXGYQVLAJ-UHFFFAOYSA-M [C@@]1(C([H])([H])[H])(C([H])([H])C([H])([H])[C@@](C23[H])(C([H])([H])O[H])C([H])([H])C([H])([H])[C@@]2([H])C(C([H])([H])[H])=C([H])[H])[C@@]3([H])C([H])([H])C([H])([H])C4([H])[C@]1(C([H])([H])[H])C([H])([H])C([H])([H])C5([H])[C@@]4(C([H])([H])[H])C([H])([H])C([H])([H])[C@]([H])(O[H])C5(C([H] BETULIN 92.42896764 106.3233817 )([H])[H])C([H])([H])[H] InChI=1S/C30H50O2/c1-19(2)20-10-15-30(18-31)17-16-28(6)21(25(20)30)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h20-25,31-32H,1,8-18H2,2-7H3/t20-,21-,22?,23?,24-,25?,27+,28-,29-,30+/m0/s1 FVWJYYTZTCVBKE-BGYIOJQESA-N OBTUSAQUINONE 88.38031528 60.32420445 C([H])(C1=O)=C(OC([H])([H])[H])\C(\C([H])=C1O[H])=C([H])\C([H])=C([H])\c2c([H])c([H])c([H])c([H])c2[H] InChI=1S/C16H14O3/c1-19-16-11-15(18)14(17)10-13(16)9-5-8-12-6-3-2-4-7-12/h2-11,17H,1H3/b8-5+,13-9+ LUZUAYAKZLCOCQ-BHHNFLQBSA-N HEMATEIN 73.22409077 65.79312931 C1(C2=C([H])C(=O)C(O[H])=C1[H])=C3[C@@](C2([H])[H])(O[H])C([H])([H])Oc4c3c([H])c([H])c(c4[O-])O[H] InChI=1S/C16H12O6/c17-10-2-1-8-13-9-4-12(19)11(18)3-7(9)5-16(13,21)6-22-15(8)14(10)20/h1-4,17,19-21H,5-6H2/p-1/t16-/m0/s1 HLUCICHZHWJHLL-INIZCTEOSA-M 2-ACETYLPYRROLE 98.28692708 111.7120287 c1(c([H])c([H])c([H])n1[H])C(C([H])([H])[H])=O InChI=1S/C6H7NO/c1-5(8)6-3-2-4-7-6/h2-4,7H,1H3 IGJQUJNPMOYEJY-UHFFFAOYSA-N CONIINE 100.1277004 105.3399787 [N+]1([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C([H])([H])C([H])([H])C([H])([H])[H] InChI=1S/C8H17N/c1-2-5-8-6-3-4-7-9-8/h8-9H,2-7H2,1H3/p+1/t8-/m1/s1 NDNUANOUGZGEPO-MRVPVSSYSA-O ANABASAMINE HYDROCHLORIDE 108.2145164 100.0316094 [NH+]1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])c(c([H])c([H])c(n2)c(c([H])c([H])c([H])n3)c3[H])c2[H])C([H])([H])[H] InChI=1S/C16H19N3/c1-19-10-3-2-6-16(19)14-7-8-15(18-12-14)13-5-4-9-17-11-13/h4-5,7-9,11-12,16H,2-3,6,10H2,1H3/p+1 TZRDBHMKTWECOV-UHFFFAOYSA-O DIHYDROROTENONE 63.71080659 53.61097374 c1(O[C@]([H])(C([H])([H])Oc(c23)c([H])c(c(OC([H])([H])[H])c2[H])OC([H])([H])[H])[C@]3(C4=O)[H])c4c([H])c([H])c5c1C([H])([H])C([H])(O5)C([H])(C([H])([H])[H])C([H])([H])[H] InChI=1S/C23H24O6/c1-11(2)16-8-14-15(28-16)6-5-12-22(24)21-13-7-18(25-3)19(26-4)9-17(13)27-10-20(21)29-23(12)14/h5-7,9,11,16,20-21H,8,10H2,1-4H3/t16?,20-,21+/m1/s1 DTFARBHXORYQBF-XHEPWMPHSA-N SELINIDIN 152.9804445 165.0566243 c1(C([H])([H])[C@@]([H])(OC(=O)\C(\C([H])([H])[H])=C([H])/C([H])([H])[H])C(O2)(C([H])([H])[H])C([H])([H])[H])c2c([H])c([H])c(c13)C([H])=C([H])C(=O)O3 InChI=1S/C19H20O5/c1-5-11(2)18(21)22-15-10-13-14(24-19(15,3)4)8-6-12-7-9-16(20)23-17(12)13/h5-9,15H,10H2,1-4H3/b11-5-/t15-/m1/s1 RRHCDWLSHIIIIT-NVWZYQMFSA-N PTERYXIN 114.2927393 84.79889756 c12c(c([H])c([H])c(C([H])=C([H])C(=O)O3)c13)OC([C@]([H])(OC(C([H])([H])[H])=O)[C@]2([H])OC(=O)\C(\C([H])([H])[H])=C([H])\C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] InChI=1S/C21H22O7/c1-6-11(2)20(24)27-18-16-14(28-21(4,5)19(18)25-12(3)22)9-7-13-8-10-15(23)26-17(13)16/h6-10,18-19H,1-5H3/b11-6+/t18-,19-/m1/s1 LYUZYPKZQDYMEE-CCGSVPMNSA-N CYTIDINE 114.0252765 99.43956064 N1(C([H])=C([H])C(=NC1=O)N([H])[H])C2([H])O[C@@]([H])([C@@]([H])(O[H])[C@@]2([H])O[H])C([H])([H])O[H] InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8?/m1/s1 UHDGCWIWMRVCDJ-ZRTZXPPTSA-N SAPPANONE A TRIMETHYL ETHER 100.720314 112.0231052 C(/C([H])([H])Oc(c12)c([H])c(c([H])c1[H])OC([H])([H])[H])(=C([H])\c(c([H])c([H])c(c3OC([H])([H])[H])OC([H])([H])[H])c3[H])\C2=O InChI=1S/C19H18O5/c1-21-14-5-6-15-17(10-14)24-11-13(19(15)20)8-12-4-7-16(22-2)18(9-12)23-3/h4-10H,11H2,1-3H3/b13-8- YKRAQIAZPKGEIC-JYRVWZFOSA-N [C@@]1(C([H])([H])[H])(C([H])([H])C2([H])[H])C([H])(C([H])([H])C([H])([H])[C@]1([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])C([H])(C23[H])C([H])([H])C([H])=C(C([H])([H])[C@]([H])(C([H])([H])C4([H])[H])OC(C([H])([H])[H])=O)[C@@] SITOSTERYL ACETATE 83.77575987 97.72362274 34C([H])([H])[H] InChI=1S/C31H52O2/c1-8-23(20(2)3)10-9-21(4)27-13-14-28-26-12-11-24-19-25(33-22(5)32)15-17-30(24,6)29(26)16-18-31(27,28)7/h11,20-21,23,25-29H,8-10,12-19H2,1-7H3/t21?,23?,25-,26?,27+,28?,29?,30-,31+/m0/s1
Load more

Recommended publications
  • 2,4-Dichlorophenoxyacetic Acid
    2,4-Dichlorophenoxyacetic acid 2,4-Dichlorophenoxyacetic acid IUPAC (2,4-dichlorophenoxy)acetic acid name 2,4-D Other hedonal names trinoxol Identifiers CAS [94-75-7] number SMILES OC(COC1=CC=C(Cl)C=C1Cl)=O ChemSpider 1441 ID Properties Molecular C H Cl O formula 8 6 2 3 Molar mass 221.04 g mol−1 Appearance white to yellow powder Melting point 140.5 °C (413.5 K) Boiling 160 °C (0.4 mm Hg) point Solubility in 900 mg/L (25 °C) water Related compounds Related 2,4,5-T, Dichlorprop compounds Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) 2,4-Dichlorophenoxyacetic acid (2,4-D) is a common systemic herbicide used in the control of broadleaf weeds. It is the most widely used herbicide in the world, and the third most commonly used in North America.[1] 2,4-D is also an important synthetic auxin, often used in laboratories for plant research and as a supplement in plant cell culture media such as MS medium. History 2,4-D was developed during World War II by a British team at Rothamsted Experimental Station, under the leadership of Judah Hirsch Quastel, aiming to increase crop yields for a nation at war.[citation needed] When it was commercially released in 1946, it became the first successful selective herbicide and allowed for greatly enhanced weed control in wheat, maize (corn), rice, and similar cereal grass crop, because it only kills dicots, leaving behind monocots. Mechanism of herbicide action 2,4-D is a synthetic auxin, which is a class of plant growth regulators.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Development of Microplate Screening System
    DEVELOPMENT OF MICROPLATE SCREENING SYSTEM AND CONSTRUCTION OF FLUORESCEIN-BASED LIBRARY FENG SUIHAN A THESIS SUMBITTED FOR THE DEGREE OF MASTER OF SCIENCE DEPARTMENT OF CHEMISTRY NATIONAL UNIVERSITY OF SINGAPORE 2010 Acknowledgements First of all, I would like to express my deep gratitude to my supervisor, Associate Professor Young-Tae Chang for his profound knowledge, invaluable guidance, constant support and inspiration throughout my graduate studies. The knowledge, both scientific and otherwise, that I accumulated under his supervision, will aid me greatly throughout my life. Next, I would like to give my sincere thanks to Dr. Marc Vendrell and Dr. Hyung-Ho Ha, for their warm support during my entire graduate studies. Besides, my sincere thinks goes to Miss Siqiang Yang, who helped me to set up the microplate screening platform. Also, I would like to thank all the graduate students of Chang lab, Animesh, Duanting, Ghosh, Jun-Seok, Yun-Kyung, Raj, for their cordiality and friendship. We had a great time together. I also benefited from all other lab members, particularly but not limited to, Siti, Yee Ling, Chew Yan, Xubin, Jeffrey, Shin Hui, Dr. Bi, Dr. Cho, Dr. Jun Li, Dr. Lees, Dr. Kang, Dr. Kim, Dr. Park, and etc. Thanks for making the working place an enjoyable one. I am grateful to Dr. Tan for recruiting me into NUS Medicinal Chemistry graduate program and I am also thankful to NUS for awarding me the research scholarship. At last, I would like to express greatest thanks to my family, particularly my wife, Bai Yang, whose encourage and understanding help me to finish my graduate study in NUS.
    [Show full text]
  • Cell Surface Mobility of GABAB Receptors Saad Bin
    Cell surface mobility of GABAB receptors Saad Bin Hannan September 2011 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy of the University College London Department of Neuroscience, Physiology, and Pharmacology University College London Gower Street London WC1E 6BT UK Declaration ii ‘I, Saad Hannan confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.' ____________________ Saad Hannan September 2011 To Ammu, Abbu, Polu Abstract ivi Abstract Type-B γ-aminobutyric acid receptors (GABABRs) are important for mediating slow inhibition in the central nervous system and the kinetics of their internalisation and lateral mobility will be a major determinant of their signalling efficacy. Functional GABABRs require R1 and R2 subunit co-assembly, but how heterodimerisation affects the trafficking kinetics of GABABRs is unknown. Here, an α- bungarotoxin binding site (BBS) was inserted into the N-terminus of R2 to monitor receptor mobility in live cells. GABABRs are internalised via clathrin- and dynamin- dependent pathways and recruited to endosomes. By mutating the BBS, a new technique was developed to differentially track R1a and R2 simultaneously, revealing the subunits internalise as heteromers and that R2 dominantly-affects constitutive internalisation of GABABRs. Notably, the internalisation profile of R1aR2 heteromers, but not R1a homomers devoid of their ER retention motif (R1ASA), is similar to R2 homomers in heterologous systems. The internalisation of R1aASA was slowed to that of R2 by mutating a di-leucine motif in the R1 C-terminus, indicating a new role for heterodimerisation, whereby R2 subunits slow the internalization of surface GABABRs.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • Isoguvacine Hydrochloride | Medchemexpress
    Inhibitors Product Data Sheet Isoguvacine hydrochloride • Agonists Cat. No.: HY-100810 CAS No.: 68547-97-7 Molecular Formula: C₆H₁₀ClNO₂ • Molecular Weight: 163.6 Screening Libraries Target: GABA Receptor Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro H2O : ≥ 100 mg/mL (611.25 mM) DMSO : 25 mg/mL (152.81 mM; Need ultrasonic) * "≥" means soluble, but saturation unknown. Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 6.1125 mL 30.5623 mL 61.1247 mL Stock Solutions 5 mM 1.2225 mL 6.1125 mL 12.2249 mL 10 mM 0.6112 mL 3.0562 mL 6.1125 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (12.71 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (12.71 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (12.71 mM); Clear solution BIOLOGICAL ACTIVITY Description Isoguvacine hydrochloride is a GABA receptor agonist. IC₅₀ & Target GABA[1] In Vitro Isoguvacine binds to a mouse forebrain synaptic membrane preparation. The specific binding is displaceable by GABA, Page 1 of 2 www.MedChemExpress.com muscimol and bicuculline but not by picrotoxin or diaminobutyric acid.
    [Show full text]
  • 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
    1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor
    [Show full text]
  • Gabaergic Signaling Linked to Autophagy Enhances Host Protection Against Intracellular Bacterial Infections
    ARTICLE DOI: 10.1038/s41467-018-06487-5 OPEN GABAergic signaling linked to autophagy enhances host protection against intracellular bacterial infections Jin Kyung Kim1,2,3, Yi Sak Kim1,2,3, Hye-Mi Lee1,3, Hyo Sun Jin4, Chiranjivi Neupane 2,5, Sup Kim1,2,3, Sang-Hee Lee6, Jung-Joon Min7, Miwa Sasai8, Jae-Ho Jeong 9,10, Seong-Kyu Choe11, Jin-Man Kim12, Masahiro Yamamoto8, Hyon E. Choy 9,10, Jin Bong Park 2,5 & Eun-Kyeong Jo1,2,3 1234567890():,; Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the brain; however, the roles of GABA in antimicrobial host defenses are largely unknown. Here we demonstrate that GABAergic activation enhances antimicrobial responses against intracel- lular bacterial infection. Intracellular bacterial infection decreases GABA levels in vitro in macrophages and in vivo in sera. Treatment of macrophages with GABA or GABAergic drugs promotes autophagy activation, enhances phagosomal maturation and antimicrobial responses against mycobacterial infection. In macrophages, the GABAergic defense is mediated via macrophage type A GABA receptor (GABAAR), intracellular calcium release, and the GABA type A receptor-associated protein-like 1 (GABARAPL1; an Atg8 homolog). Finally, GABAergic inhibition increases bacterial loads in mice and zebrafish in vivo, sug- gesting that the GABAergic defense plays an essential function in metazoan host defenses. Our study identified a previously unappreciated role for GABAergic signaling in linking antibacterial autophagy to enhance host innate defense against intracellular bacterial infection. 1 Department of Microbiology, Chungnam National University School of Medicine, Daejeon 35015, Korea. 2 Department of Medical Science, Chungnam National University School of Medicine, Daejeon 35015, Korea.
    [Show full text]
  • 5994392 Tion of Application No. 67375.734 Eb3-1685, PEN. T
    USOO5994392A United States Patent (19) 11 Patent Number: 5,994,392 Shashoua (45) Date of Patent: Nov.30, 1999 54 ANTIPSYCHOTIC PRODRUGS COMPRISING 5,120,760 6/1992 Horrobin ................................. 514/458 AN ANTIPSYCHOTICAGENT COUPLED TO 5,141,958 8/1992 Crozier-Willi et al. ................ 514/558 AN UNSATURATED FATTY ACID 5,216,023 6/1993 Literati et al. .......................... 514/538 5,246,726 9/1993 Horrobin et al. ....................... 424/646 5,516,800 5/1996 Horrobin et al. ....................... 514/560 75 Inventor: Victor E. Shashoua, Brookline, Mass. 5,580,556 12/1996 Horrobin ................................ 424/85.4 73 Assignee: Neuromedica, Inc., Conshohocken, Pa. FOREIGN PATENT DOCUMENTS 30009 6/1981 European Pat. Off.. 21 Appl. No.: 08/462,820 009 1694 10/1983 European Pat. Off.. 22 Filed: Jun. 5, 1995 09 1694 10/1983 European Pat. Off.. 91694 10/1983 European Pat. Off.. Related U.S. Application Data 59-025327 2/1984 Japan. 1153629 6/1989 Japan. 63 Continuation of application No. 08/080,675, Jun. 21, 1993, 1203331 8/1989 Japan. abandoned, which is a continuation of application No. 07/952,191, Sep. 28, 1992, abandoned, which is a continu- (List continued on next page.) ation of application No. 07/577,329, Sep. 4, 1990, aban doned, which is a continuation-in-part of application No. OTHER PUBLICATIONS 07/535,812,tion of application Jun. 11, No. 1990, 67,375.734 abandoned, Eb3-1685, which is a continu-PEN. T. Higuchi et al. 66 Prodrugs as Noye Drug Delivery Sys 4,933,324, which is a continuation-in-part of application No.
    [Show full text]
  • Effects of Metabolic Inhibitors on the Translocation of Auxins
    EFFECTS OF METABOLIC INHIBITORS ON THE TRANSLOCATION OF AUXINS By DAMELIS DIAZ DE CEQUEA q Licenciado in Biology Universidad of Oriente Cumana, Venezuela 1976 Submitted to the Faculty of the Graduate College of the Oklahoma State University in partial fulfillment of the requirements for the Degree of MASTER OF SCIENCE May, 1986 -rkto~~~ I 1:{ (; 0 5'/Je Cop " EFFECTS OF METABOLIC INHIBITORS ON THE TRANSLOCATION OF AUXINS Thesis Approved: 1251232 ~ ii ACKNOWLEDGMENTS I wish to express my most sincere gratitude to Dr. Eddie Basler for his guidance, time and training during the course of this research. I wish to thank Dr. Glenn W. Todd and Dr. Becky Johnson for being members of my graduate committee. I also want to thank Jean Pittman Winters, Trina Wheless, and Roberto Machado for their valuable help received during experiment preparations, and Bobby Winters for his time dedicated to preparing some of the computer programs. Special acknowledgement is due to my husband Hernan, my son Hernan Alejandro, and my family for their constant love and support during my graduate career, without them I would not have been able to achieve this goal. I want to express my gratitude to Dr. John Vitek, Assistant Dean of the Graduate Collage, and Dr. Glenn Todd, Botany Department Head, for giving me the opportunity to study in this University. Finally, I want to recognize the financial support received from Universidad de Oriente Cumana, Venezuela during my time in the U.S.A. iii TABLE OF CONTENTS Chapter Page I. INTRODUCTION. • . • • . • 1 II. MATERIALS AND METHODS....................................... 8 III. RESULTS ..•....•.................................•..........• 11 Comparison of the Effect of DCCD and1RIDS on the Tray~location of 2,4,5-T-1- C and IAA -1- C.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]